ESTA News

Establishment Labs Reports Second Quarter 2025 Financial Results

ESTA

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the second quarter ended June 30, 2025. Second Quarter Highlights and Outlook (Unaudited) Second quarter worldwide revenue of $51.3 million, an increase of 16.3% from the year ago period. Revenue included $10.3 million of Motiva sales in the Un

August 7, 2025Earnings
Read more →

Establishment Labs Hosting Investor Day on June 12

ESTA

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, will host its previously announced analyst and investor event in New York City on June 12, 2025 beginning at 1pm ET. A live and archived webcast of presentations and Q&A sessions on June 12 will be available on the Investors section of the Establishment Labs website at www.es

Needham Upgrades Establishment Labs Hldgs to Buy, Announces $48 Price Target

ESTA

May 14, 2025
Read more →

Establishment Labs Hldgs Affirms FY2025 Sales Guidance of $205.00M-$210.00M vs $206.92M Est

ESTA

May 7, 2025
Read more →

Establishment Labs Hldgs Q1 EPS $(0.70) Beats $(0.81) Estimate, Sales $41.38M Beat $41.11M Estimate

ESTA

May 7, 2025
Read more →

Establishment Labs Holdings Appoints Peter Caldini As CEO, Effective May 7, 2025

ESTA

May 7, 2025
Read more →

Correction: Needham Initiates Coverage On Establishment Labs Hldgs to Hold (Rating Change From Reiterate to Initiates)

ESTA

April 14, 2025
Read more →

Needham Reiterates Hold on Establishment Labs Hldgsto Hold

ESTA

April 14, 2025
Read more →

Establishment Labs Holdings Sees Prelim. Q1 Revenue ~$41.4M Vs $40.762M Est.

ESTA

April 10, 2025
Read more →

Stephens & Co. Reiterates Overweight on Establishment Labs Hldgs, Maintains $52 Price Target

ESTA

March 6, 2025
Read more →

Establishment Labs Hldgs Affirms FY2025 Sales Guidance of $205.00M-$210.00M vs $206.24M Est

ESTA

February 26, 2025
Read more →

Establishment Labs Hldgs Q4 EPS $(1.19) Misses $(0.62) Estimate, Sales $44.51M Miss $44.61M Estimate

ESTA

February 26, 2025
Read more →

Establishment Labs Announces Peter Caldini To Become Interim CEO Effective March 1, 2025; Anticipates 2024 Revenue Between $166M-$166.5M, Q4 Revenue Between $44.5M-$45M; $3.2M From U.S. Motiva Sales

ESTA

January 13, 2025
Read more →

Exploring Establishment Labs Hldgs's Earnings Expectations

ESTA

November 6, 2024
Read more →

Establishment Labs Announces 3-Year Mia Femtech Clinical Results At 9th World Symposium On Ergonomic Implants; There Were Also No Reports Of Infection, Hematoma, Or Seroma Requiring Intervention In The Study And No Reports Of Changes In Nipple Or Breast S

ESTA

October 31, 2024
Read more →

The Analyst Landscape: 5 Takes On Establishment Labs Hldgs

ESTA

May 22, 2024
Read more →

Citigroup Downgrades Establishment Labs Hldgs to Neutral, Maintains Price Target to $60

ESTA

May 22, 2024
Read more →